IGC Pharma, Inc.
IGC · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.43 | -0.17 | 0.13 | -0.81 |
| FCF Yield | -5.32% | -6.02% | -4.11% | -5.15% |
| EV / EBITDA | -12.67 | -14.26 | -17.20 | -15.11 |
| Quality | ||||
| ROIC | -35.23% | -30.33% | -21.45% | -28.15% |
| Gross Margin | 51.83% | 46.95% | 46.67% | 40.47% |
| Cash Conversion Ratio | 1.15 | 0.88 | 0.61 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | -6.29% | 1.88% | 11.70% | 12.50% |
| Free Cash Flow Growth | -31.13% | -70.65% | 33.33% | -44.21% |
| Safety | ||||
| Net Debt / EBITDA | 0.33 | 0.14 | 0.13 | 0.04 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.14 | 0.13 | 0.13 | 0.11 |
| Cash Conversion Cycle | 48.67 | 265.93 | 264.92 | 368.92 |